
AMCP comments on Trump Administration demands for manufacturers to take action on Most-Favored-Nation pricing scheme
On November 20, HHS released an Interim Final Rule with Comment Period (IFC) establishing a Most Favored Nation (MFN) Model for Medicare Part B drugs. The MFN Model will calculate the payment rate for included drugs based on a price that reflects the lowest per capita GDP-adjusted price among a group of OECD countries, with an additional flat payment based on the average payment for MFN Model drugs in 2019 adjusted quarterly for inflation.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.